The presence of anti-basement membrane zone antibodies in the sera of patients with non-bullous lupus erythematosus

British Journal of Dermatology

Volumn 136, Issue 2, 1997, Pages 222-226

  Ishikawa, O ^a   Zaw, K K ^a   Miyachi, Y ^a   Hashimoto, T ^b   Tanaka, T ^c  

^a GUNMA UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASEMENT MEMBRANE ANTIBODY;

ADULT; AGED; ARTICLE; BULLOUS SKIN DISEASE; CLINICAL ARTICLE; DISCOID LUPUS ERYTHEMATOSUS; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MALE; PRIORITY JOURNAL; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

EID: 0031040340     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb14900.x     Document Type: Article

References (14)

1. Camisa C, Sharma HM. Vesiculobullous systemic lupus erythematosus. J Am Acad Dermatol 1983: 9: 924-33.
2. Gammon WR, Briggaman RA, Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol 1993: 100 (Suppl.): 28s-34s.
3. Yell JA, Allen J, Wojnarowska F et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995: 132: 921-8.
4. Tan EM, Cohen AS, Freis JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982: 25: 1271-7.
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980: 23: 581-90.
6. Gammon WR, Briggaman RA, Inman AO et al. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by immunofluorescence on 1.0mol sodium chloride separated skin. J Invest Dermatol 1984: 82: 139-44.
7. Sugi T, Hashimoto T, Hibi T, Nishikawa T. Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them. J Clin Invest 1989: 84: 1050-5.
8. Hashimoto T, Amagai M, Ebihara T et al. Further analysis of epitopes for human monoclonal anti-basement membrane zone antibodies produced by stable human hybridoma cell lines constructed with Epstein-Barr virus transformation. J Invest Dermatol 1993: 100: 310-15.
9. Woodley DT, Briggaman RA, O'Keefe EJ et al. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984: 310: 1007-13.
10. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen, BP-180. J Invest Dermatol 1992: 99: 243-50.
11. Gammon WR, Briggaman RA. Bullous eruption of systemic lupus erythematosus. In: Management of Blistering Diseases (Wojnarowska F, Briggaman RA, eds). London: Chapman and Hall, 1990: 263-75.
12. Barton DD, Fine J-D, Gammon WR, Sams WM Jr. Bullous systemic lupus erythematosus: an unusual clinical course and detectable circulating autoantibodies to the epidermolysis bullosa antigen. J Am Acad Dermatol 1986: 15: 369-73.
13. Gammon WR, Woodley DT, Dole KC, Briggaman RA. Evidence that anti-basement membrane zone antibodies in bullous eruption of systemic lupus erythematosus recognize epidermolysis bullosa acquisita autoantigen. J Invest Dermatol 1985: 84: 472-6.
14. Woodley DT, Burgeson RE, Lunstrum G, et al. Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J Clin Invest 1988: 81: 683-7.